Back to results
US 8,008,003 B2Granted
Gene expression profiling of EGFR positive cancer
AssigneeGenomic Health, Inc.
InventorsJoffre B. Baker, Maureen T. Cronin, Steve Shak, Jose Baselga
Life of this patent
Estimating the term…
Abstract
The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Claims15
A method for predicting the likelihood that a human colon cancer patient will exhibit a clinically beneficial patient response to treatment with cetuximab, the method comprising:
- a) assaying a normalized level of a predictive RNA transcript in a sample comprising ErbB1-expressing colon cancer cells obtained from said patient, wherein the predictive RNA transcript is the transcript of laminin gamma 2 (LAMC2);
- b) analyzing the normalized level of the LAMC2 transcript;
- and
- c) predicting the likelihood of response of the patient to treatment with cetuximab by comparing the normalized level of the LAMC2 transcript to gene expression data obtained from reference samples derived from patients with colon cancer, wherein an increased normalized level of LAMC2 RNA transcript correlates with a decreased likelihood of response to treatment with cetuximab.
1 more element
Dependencies are inferred from the claim text.